Evaluation of the effect of Livergol in reducing peripheral neuropathies induced by cisplatin

Evaluation of the effect of Livergol (silymarin extract) in reducing peripheral neuropathies induced by cisplatin in patients undergoing chemotherapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200825048515N29

Enrollment

Registered

2021-04-06

Start date

2021-04-04

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer. Malignant (primary) neoplasm, unspecified

Interventions

Intervention 1: Intervention group: In addition to cisplatin chemotherapy, patients in this group will be treated with Livergol 140 mg tablets 3 times a day for 90 days. Intervention 2: Control group:

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Newly diagnosed cancer and undergoing chemotherapy with cisplatin Having symptoms of peripheral neuropathy after starting chemotherapy Consent to participate in this study

Exclusion criteria

Exclusion criteria: Having multiple myeloma Having previous neurological disorders Having diseases that give rise to peripheral neuropathy (such as diabetes)

Design outcomes

Primary

Measure	Time frame
Chemotherapy induced peripheral neuropathy score. Timepoint: Before and after the intervention. Method of measurement: Chemotherapy Induced Peripheral Neuropathy Assessment Tool (CIPNAT).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Haji Gholami

Esfahan University of Medical Sciences

ali_hajigholami@yahoo.com+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026